Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 512 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese MOST POPULAR New on NCI’s Websites for October 2019 October 3, 2019 “Your Stories” Podcast: Amplifying Patient Voices September 8, 2020 Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... May 7, 2021 El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Load more HOT NEWS Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... Honoring Other’s Wishes A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... One Year in Cancer Research and Much to Celebrate
